Clinical

Videos

“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.

Cxbladder tests identify high-impact and low-impact tumors

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Articles

The novel oncolytic immunotherapy CG0070 is also currently being explored as a in a phase 3 monotherapy trial. 

Combo of nivolumab and novel oncolytic immunotherapy explored in bladder cancer

Michael S. Cookson, MD, previews the 2021 AUA Annual Meeting, with a focus on prostate, bladder, and kidney cancer. His in-depth analysis covers the plenary sessions, late-breaking abstracts, and other abstracts of interest.

2021 AUA Annual Meeting Preview: Prostate, Bladder, and Kidney Cancer

Over half of patients had pathologic downstaging after receiving the neoadjuvant regimen.  

Neoadjuvant pembrolizumab regimen shows benefit in MIBC

The FDA has converted the accelerated approval of frontline pembrolizumab in advanced bladder cancer  to a full approval and revised the indication to cover the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.

FDA grants full approval to pembrolizumab in frontline bladder cancer

 is a urologist with Central Ohio Urology Group in Gahanna.

Urologists and medical oncologists should collaborate to tailor therapy to the specific needs of the patient.

Upper tract urothelial carcinoma case illustrates rapidly changing treatment landscape

Nonsurgical primary chemoablation with the mitomycin-containing reverse thermal gel UGN-102 showed promise as an alternative to repetitive surgery for patients with low-grade non–muscle invasive bladder cancer.

Primary chemoablation with UGN-102 effective in low-grade NMIBC

In a news release, Checkmate -274 primary investigator Matthew Galsky, MD, hailed the approval as a “major milestone for patients who have undergone major surgery to remove the bladder or parts of the urinary tract and are in need of additional treatment approaches that can help reduce the risk of their UC returning."

FDA approves adjuvant nivolumab in bladder cancer

Ventana MMR RxDx Panel is a qualitative immunohistochemistry test that assesses a panel of MMR proteins to help guide clinicians in their  treatment decisions. 

FDA approves dostarlimab companion diagnostic for use across dMMR solid tumors 

The approval provides urologists with another tool for the treatment of patients with genitourinary cancers and underscores the rapidly growing significance of genetic testing in the field of urology.

Bladder Cancer